Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine

In the original publication, two values provided for landmark survival for patients treated with gemcitabine were incorrectly listed in the text. On page 562, paragraph 3, the text listed that: “for TNBC: 50%, 31%, 20%, and 3%, respectively, for HR+/HER2−: 51%, 27%, 10%, and 3%, respectively”. The correct values should be “for TNBC: 50%, 31%, 11%, and 3%, respectively, for HR+/HER2−: 51%, 27%, 10%, and 7%, respectively”. The correct values are consistent with those listed in Table 2.